• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

解整合素金属蛋白酶（ADAMs）的泛癌分析：一种用于预后以及化疗和免疫治疗反应的有前景的生物标志物。

Pan-cancer analysis of ADAMs: A promising biomarker for prognosis and response to chemotherapy and immunotherapy.

作者信息

Ma Bo, Yu Riyue

机构信息

Department of Stomatology, Beijing Shijitan Hospital, Capital Medical University, Beijing, China.

出版信息

Front Genet. 2023 Apr 4;14:1105900. doi: 10.3389/fgene.2023.1105900. eCollection 2023.

DOI:10.3389/fgene.2023.1105900
PMID:37082201
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10110990/
Abstract

Members of a disintegrin and metalloproteinase (ADAM) family play a vital role in cancer development. However, a comprehensive analysis of the landscape of the ADAM family in pan-cancer remains to be performed. The correlation of the expression level and prognostic value with ADAMs in a pan-cancer cohort and the relationship between ADAMs and the stemness score, tumour microenvironment (TME), chemotherapy-related drug sensitivity, immune subtype, and immunotherapy outcome were investigated. ADAMs were differentially expressed between tumour and para-carcinoma tissues in the pan-cancer cohort, and the expression of ADAMs was significantly correlated with patient prognosis. Furthermore, ADAMs were significantly correlated with the stromal score and immune score based on the TME analysis. Additionally, ADAMs were also correlated with DNAss and RNAss in the pan-cancer cohort. On investigating the CellMiner database, ADAMs were revealed to be significantly correlated with the sensitivity of various drugs, including raloxifene and tamoxifen. Moreover, in the IMvigor210 and GSE78220 cohorts, ADAMs were correlated with immunotherapy response and immune activation genes. Furthermore, quantitative real-time polymerase chain reaction (qRT-PCR) and immunohistochemistry (IHC) were utilised to determine the differential level of ADAM9 in cancer and para-carcinoma tissues in patients' samples. This study elucidates the importance of ADAMs in cancer progression and lays a foundation for further exploration of ADAMs as potential pan-cancer targets.

摘要

解整合素金属蛋白酶（ADAM）家族成员在癌症发展中起着至关重要的作用。然而，对泛癌中ADAM家族全貌的综合分析仍有待进行。本研究调查了泛癌队列中ADAMs的表达水平与预后价值的相关性，以及ADAMs与干性评分、肿瘤微环境（TME）、化疗相关药物敏感性、免疫亚型和免疫治疗结果之间的关系。在泛癌队列中，肿瘤组织和癌旁组织之间ADAMs存在差异表达，且ADAMs的表达与患者预后显著相关。此外，基于TME分析，ADAMs与基质评分和免疫评分显著相关。另外，在泛癌队列中，ADAMs也与DNAss和RNAss相关。通过研究CellMiner数据库发现，ADAMs与多种药物的敏感性显著相关，包括雷洛昔芬和他莫昔芬。此外，在IMvigor210和GSE78220队列中，ADAMs与免疫治疗反应和免疫激活基因相关。此外，利用定量实时聚合酶链反应（qRT-PCR）和免疫组织化学（IHC）来确定患者样本中癌组织和癌旁组织中ADAM9的差异水平。本研究阐明了ADAMs在癌症进展中的重要性，并为进一步探索ADAMs作为潜在的泛癌靶点奠定了基础。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7097/10110990/62be98b31bf9/fgene-14-1105900-g010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7097/10110990/761a910ab2b8/fgene-14-1105900-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7097/10110990/9f41d9a227e4/fgene-14-1105900-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7097/10110990/1cdb5522d1f9/fgene-14-1105900-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7097/10110990/aefff3ce6ab8/fgene-14-1105900-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7097/10110990/f401a2310f60/fgene-14-1105900-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7097/10110990/72cc49add767/fgene-14-1105900-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7097/10110990/81f431a914cd/fgene-14-1105900-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7097/10110990/45ae6346a55c/fgene-14-1105900-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7097/10110990/85b8e60660bc/fgene-14-1105900-g009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7097/10110990/62be98b31bf9/fgene-14-1105900-g010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7097/10110990/761a910ab2b8/fgene-14-1105900-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7097/10110990/9f41d9a227e4/fgene-14-1105900-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7097/10110990/1cdb5522d1f9/fgene-14-1105900-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7097/10110990/aefff3ce6ab8/fgene-14-1105900-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7097/10110990/f401a2310f60/fgene-14-1105900-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7097/10110990/72cc49add767/fgene-14-1105900-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7097/10110990/81f431a914cd/fgene-14-1105900-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7097/10110990/45ae6346a55c/fgene-14-1105900-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7097/10110990/85b8e60660bc/fgene-14-1105900-g009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7097/10110990/62be98b31bf9/fgene-14-1105900-g010.jpg

相似文献

1
Pan-cancer analysis of ADAMs: A promising biomarker for prognosis and response to chemotherapy and immunotherapy.解整合素金属蛋白酶（ADAMs）的泛癌分析：一种用于预后以及化疗和免疫治疗反应的有前景的生物标志物。
Front Genet. 2023 Apr 4;14:1105900. doi: 10.3389/fgene.2023.1105900. eCollection 2023.
2
Pan-Cancer Analysis of the TRP Family, Especially TRPV4 and TRPC4, and Its Expression Correlated with Prognosis, Tumor Microenvironment, and Treatment Sensitivity.泛癌症分析 TRP 家族，特别是 TRPV4 和 TRPC4，及其表达与预后、肿瘤微环境和治疗敏感性的相关性。
Biomolecules. 2023 Feb 2;13(2):282. doi: 10.3390/biom13020282.
3
Pan-cancer analyses of clinical prognosis, immune infiltration, and immunotherapy efficacy for TRPV family using multi-omics data.利用多组学数据对TRPV家族进行临床预后、免疫浸润和免疫治疗疗效的泛癌分析。
Heliyon. 2023 Jun 3;9(6):e16897. doi: 10.1016/j.heliyon.2023.e16897. eCollection 2023 Jun.
4
TMX family genes and their association with prognosis, immune infiltration, and chemotherapy in human pan-cancer.TMX家族基因及其在人类泛癌中与预后、免疫浸润和化疗的关联。
Aging (Albany NY). 2023 Dec 21;15(24):15064-15083. doi: 10.18632/aging.205332.
5
Integrative analysis revealed a correlation of PIAS family genes expression with prognosis, immunomodulation and chemotherapy.综合分析显示，PIAS 家族基因的表达与预后、免疫调节和化疗相关。
Eur J Med Res. 2024 Mar 25;29(1):195. doi: 10.1186/s40001-024-01795-7.
6
Characterization of stem cell landscape and identification of stemness-relevant prognostic gene signature to aid immunotherapy in colorectal cancer.鉴定结直肠癌细胞干性相关的预后基因特征，以辅助免疫治疗。
Stem Cell Res Ther. 2022 Jun 9;13(1):244. doi: 10.1186/s13287-022-02913-0.
7
The Pan-Cancer Landscape of Crosstalk Between TRP Family and Tumour Microenvironment Relevant to Prognosis and Immunotherapy Response.跨癌种 TRP 家族与肿瘤微环境相互作用与预后和免疫治疗反应相关的全景图。
Front Immunol. 2022 Apr 13;13:837665. doi: 10.3389/fimmu.2022.837665. eCollection 2022.
8
FAM3 family genes are associated with prognostic value of human cancer: a pan-cancer analysis.FAM3 家族基因与人类癌症的预后价值相关：泛癌症分析。
Sci Rep. 2023 Sep 13;13(1):15144. doi: 10.1038/s41598-023-42060-x.
9
The role of Angiogenesis and remodeling (AR) associated signature for predicting prognosis and clinical outcome of immunotherapy in pan-cancer.血管生成和重塑（AR）相关特征在预测免疫治疗泛癌患者预后和临床结局中的作用。
Front Immunol. 2022 Nov 21;13:1033967. doi: 10.3389/fimmu.2022.1033967. eCollection 2022.
10
Identification of Hypoxia-Related Subtypes, Establishment of Prognostic Models, and Characteristics of Tumor Microenvironment Infiltration in Colon Cancer.结肠癌中缺氧相关亚型的鉴定、预后模型的建立及肿瘤微环境浸润特征
Front Genet. 2022 Jun 17;13:919389. doi: 10.3389/fgene.2022.919389. eCollection 2022.

引用本文的文献

1
Emerging roles of ADAM6 and PRSS1 as novel diagnostic/prognostic biomarkers for acute lymphoblastic and myeloid leukemia in adults.ADAM6和PRSS1作为成人急性淋巴细胞白血病和急性髓细胞白血病新型诊断/预后生物标志物的新作用。
BMC Cancer. 2025 May 17;25(1):884. doi: 10.1186/s12885-025-14292-9.
2
A pan-cancer study of ADAM9's immunological function and prognostic value particularly in liver cancer.一项针对 ADAM9 免疫功能及其在肝癌中预后价值的泛癌研究。
Sci Rep. 2024 Nov 6;14(1):26862. doi: 10.1038/s41598-024-76049-x.
3
Causal inference of the effect of blood proteome on the risk of head and neck cancer: two-sample Mendelian randomization.

本文引用的文献

1
ADAM12 is an independent predictor of poor prognosis in liver cancer.ADAM12 是肝癌预后不良的独立预测因子。
Sci Rep. 2022 Apr 22;12(1):6634. doi: 10.1038/s41598-022-10608-y.
2
Cancer statistics in China and United States, 2022: profiles, trends, and determinants.中国和美国 2022 年癌症统计数据：概况、趋势和决定因素。
Chin Med J (Engl). 2022 Feb 9;135(5):584-590. doi: 10.1097/CM9.0000000000002108.
3
The ECM: To Scaffold, or Not to Scaffold, That Is the Question.细胞外基质：构建还是不构建，这是个问题。
血液蛋白质组对头颈癌风险影响的因果推断：两样本孟德尔随机化研究
Discov Oncol. 2024 Jul 10;15(1):277. doi: 10.1007/s12672-024-01128-4.
Int J Mol Sci. 2021 Nov 24;22(23):12690. doi: 10.3390/ijms222312690.
4
ADAM9-Responsive Mesoporous Silica Nanoparticles for Targeted Drug Delivery in Pancreatic Cancer.用于胰腺癌靶向给药的ADAM9响应性介孔二氧化硅纳米颗粒
Cancers (Basel). 2021 Jul 1;13(13):3321. doi: 10.3390/cancers13133321.
5
Planning for tomorrow: global cancer incidence and the role of prevention 2020-2070.规划未来：2020 - 2070年全球癌症发病率及预防的作用
Nat Rev Clin Oncol. 2021 Oct;18(10):663-672. doi: 10.1038/s41571-021-00514-z. Epub 2021 Jun 2.
6
mir-126-5p Promotes Cisplatin Sensitivity of Non-Small-Cell Lung Cancer by Inhibiting ADAM9.miR-126-5p 通过抑制 ADAM9 促进非小细胞肺癌对顺铂的敏感性。
Biomed Res Int. 2021 May 15;2021:6622342. doi: 10.1155/2021/6622342. eCollection 2021.
7
Hypoxia-inducible factor-dependent ADAM12 expression mediates breast cancer invasion and metastasis.缺氧诱导因子依赖性 ADAM12 表达介导乳腺癌的侵袭和转移。
Proc Natl Acad Sci U S A. 2021 May 11;118(19). doi: 10.1073/pnas.2020490118.
8
Extracellular matrix and its therapeutic potential for cancer treatment.细胞外基质及其在癌症治疗中的治疗潜力。
Signal Transduct Target Ther. 2021 Apr 23;6(1):153. doi: 10.1038/s41392-021-00544-0.
9
Systems epidemiology and cancer: A review of the National Institutes of Health extramural grant portfolio 2013-2018.系统流行病学与癌症：对美国国立卫生研究院 2013-2018 年校外资助组合的回顾。
PLoS One. 2021 Apr 15;16(4):e0250061. doi: 10.1371/journal.pone.0250061. eCollection 2021.
10
ADAM and ADAMTS Proteins, New Players in the Regulation of Hepatocellular Carcinoma Microenvironment.ADAM和ADAMTS蛋白：肝细胞癌微环境调控中的新角色
Cancers (Basel). 2021 Mar 29;13(7):1563. doi: 10.3390/cancers13071563.